Literature DB >> 21980039

Timing of ganciclovir administration in glioma gene therapy using HSVtk gene-transduced mesenchymal stem cells.

Shinji Amano1, Chunyu Gu, Shinichiro Koizumi, Tsutomu Tokuyama, Hiroki Namba.   

Abstract

BACKGROUND: An established C6 glioma was successfully treated with intratumoral injection of mesenchymal stem cells transduced with HSVtk gene (MSCtk) and systemic administration of ganciclovir (GCV). The best timing of GCV administration after the MSCtk implantation was studied.
MATERIALS AND METHODS: GCV administration was started from 2 days before and 1, 3 and 7 days after the MSCtk administration under both in vitro and in vivo conditions.
RESULTS: The C6 cells were completely eradicated in vitro when GCV administration was started from day -2, 1, and 3. Animals with intracranial tumor survived longer when GCV was administered earlier after MSCtk administration. This may, mainly, reflect the difference in the MSCtk/C6 ratio at the time of GCV administration because this ratio drastically decreases during the delay of GCV administration.
CONCLUSION: When using a slowly growing vector cell as MSCtk, GCV should be administered soon after MSCtk implantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21980039

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  6 in total

1.  Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

Authors:  Adam Nowakowski; Katarzyna Drela; Justyna Rozycka; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

2.  Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo.

Authors:  Antonella Mangraviti; Stephany Yi Tzeng; Kristen Lynn Kozielski; Yuan Wang; Yike Jin; David Gullotti; Mariangela Pedone; Nitsa Buaron; Ann Liu; David R Wilson; Sarah K Hansen; Fausto J Rodriguez; Guo-Dong Gao; Francesco DiMeco; Henry Brem; Alessandro Olivi; Betty Tyler; Jordan J Green
Journal:  ACS Nano       Date:  2015-02-10       Impact factor: 15.881

Review 3.  Nanoparticles for Stem Cell Therapy Bioengineering in Glioma.

Authors:  Henry Ruiz-Garcia; Keila Alvarado-Estrada; Sunil Krishnan; Alfredo Quinones-Hinojosa; Daniel M Trifiletti
Journal:  Front Bioeng Biotechnol       Date:  2020-12-07

4.  Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma.

Authors:  Martin J Hicks; Maria J Chiuchiolo; Douglas Ballon; Jonathan P Dyke; Eric Aronowitz; Kosuke Funato; Viviane Tabar; David Havlicek; Fan Fan; Dolan Sondhi; Stephen M Kaminsky; Ronald G Crystal
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

5.  HSV-TK Expressing Mesenchymal Stem Cells Exert Inhibitory Effect on Cervical Cancer Model.

Authors:  Azra Kenarkoohi; Taravat Bamdad; Masoud Soleimani; Hoorieh Soleimanjahi; Ali Fallah; Shahab Falahi
Journal:  Int J Mol Cell Med       Date:  2020-08-10

6.  Glioblastoma Bystander Cell Therapy: Improvements in Treatment and Insights into the Therapy Mechanisms.

Authors:  Marta Guerra-Rebollo; Carolina Nogueira de Moraes; Cristina Alcoholado; Carolina Soler-Botija; Lourdes Sanchez-Cid; Olaia F Vila; Oscar Meca-Cortés; Sara Ramos-Romero; Nuria Rubio; José Becerra; Jeronimo Blanco; Cristina Garrido
Journal:  Mol Ther Oncolytics       Date:  2018-09-15       Impact factor: 7.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.